The National Association of Testing Authorities has signed an MoU with the Victorian Asbestos Eradication Agency to ensure the reliability of asbestos testing in government buildings.
Evident has announced its new APAC headquarters in Singapore and opened entries for its Global Image of the Year Scientific Light Microscopy Award.
The partnership will bring together Microba's proprietary gut microbiome analysis platform with Illumina's next-generation sequencing tools.
The companies will form a strategic alliance under common ownership to provide A/NZ researchers with improved access to research technologies and supplies.
Illumina has announced the acquisition of BlueBee — a cloud-based software company that provides genomics analysis solutions for research and clinical customers.
Dr Pierre-Alain Ruffieux has been appointed Lonza's CEO, just a few weeks after the company announced a strategic collaboration agreement with biotech company Moderna.
Serving science company Thermo Fisher Scientific has announced several new measures as part of its efforts to combat the COVID-19 pandemic.
Thermo Fisher Scientific has proposed to acquire QIAGEN and appointed Paul G Parker as Senior Vice President, Strategy and Corporate Development.
Trajan Nutrition has signed an MOU with the South Australian Health and Medical Research Institute to accelerate the translation in the global market of nutrition testing research.
Science and technology company Merck has opened its new Sydney office in the innovation hub of Macquarie Park — a move that seeks to further the company's local growth opportunities.
The Melbourne drug development company has announced Dr Tim Oldham as its new CEO and signed a commercial agreement for its i-body platform with GE Healthcare.
Thermo Fisher Scientific has entered into a collaboration with Cedars-Sinai and elected Debora Spar to its board of directors.
Integrated DNA Technologies has announced two new partnerships as part of its mission to break down the barriers in genomics research.
The partnership fuses IDT's oligo synthesis with 3CR's PACE Genotyping Master Mix and expertise in designing assays.
With the support of the Victorian Government, Trajan Scientific and Medical plans to invest $2.4 million in the expansion of its Melbourne facility over the next three years.